An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

NCT05884255 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Gastroenteropancreatic Neuroendocrine Tumor

Interventions

DRUG: Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide
DRUG: long-acting Octreotide

Sponsor

Jiangsu HengRui Medicine Co., Ltd.